Claims
- 1. An antibiotic compound in substantially pure form designated CL-1957A having the structural formula ##STR3## or a pharmaceutically acceptable salt thereof; compound CL-1957A characterized by:
- (a) a molecular weight of 540 atomic mass units;
- (b) a melting point of 41.degree.-44.degree. C. (with prior softening);
- (c) an optical rotation, [.alpha.].sub.D.sup.23 of -157.degree. (0.7 in chloroform);
- (d) an ultraviolet absorption spectrum in methanol (free acid form) showing an inflection at 290 nm and end absorption below 260 nm;
- (e) an ultraviolet absorption spectrum in methanol (carboxylate anion form) showing maxima at 240 nm (a =61.1), 287 nm (a =6.6), and 378 nm (a =3.5);
- (f) an infrared absorption spectrum in chloroform showing principal absorption peaks at 2975, 2940, 1715, 1700 (shoulder), 1645, 1455, 1375, 1255, 1105, and 965 reciprocal centimeters;
- (g) a 360 MHz proton magnetic resonance spectrum in deuterochloroform solution showing signals at 0.77 (doublet, 3 protons), 0.97 (doublet, 3 protons), 1.03 (triplet, 3 protons), 1.05 (doublet, 3 protons), 1.10 (doublet, 3 protons), 1.13 (doublet, 3 protons), 1.73 (multiplet, 1 proton), 1.80 (singlet, 3 protons), 1.88 (doublet of doublets, 1 proton), 2.06 (triplet, 2 protons), 2.11 (singlet, 3 protons), 2.17 (multiplet, 1 proton), 2.17 (quartet, 2 protons), 2.51 (multiplet, 1 proton), 2.65 (multiplet, 1 proton), 2.80 (multiplet, 1 proton), 3.56 (triplet, 1 proton), 3.64 multiplet, 1 proton), 4.97 (doublet of doublets, 1 proton), 5.06 (doublet, 1 proton), 5.21 (doublet, 1 proton), 5.57 (multiplet, 1 proton), 5.66 (singlet, 1 proton), 5.70 (doublet of doublets, 1 proton), 5.97 (doublet, 1 proton), 5.98 (doublet, 1 proton), 6.62 (doublet, 1 proton), and 6.93 (doublet of doublets, 1 proton) parts per million downfield from tetramethylsilane; and h) a 90.5 MHz .sup.13 C nuclear magnetic resonance spectrum in deuterochloroform solution showing principal signals at 215.08, 171.01, 164.30, 161.06, 15l.47, 137.90, 136.44, 135.53, 135.18, 130.18, 128.14, 128.01, 122.76, 120.05, 116.85, 81.49, 74.32, 46.74, 45.70, 45.65, 40.84, 33.58, 32.21, 26.61, 20.85, 18.65, 16.08, 13.68, 13.62, 13.08, 12.61, and 12.38 parts per million downfield from tetramethylsilane.
- 2. A pharmaceutical composition comprising a solution of the compound CL-1957A as defined in claim 1 and absolute ethanol.
- 3. A pharmaceutical composition comprising a solution of the compound CL-1957A as defined in claim 1 and 95% ethanol.
- 4. A pharmaceutical composition comprising a solution of the compound CL-1957A as defined in claim 1 and propylene glycol.
- 5. A pharmaceutical composition in accordance with claim 3 further containing ascorbic acid.
CROSS-REFERENCE TO RELATED APPPLICATIONS
This application is a continuation of Ser. No. 641,984 filed Aug. 21, 1984, now abandoned, which in turn is a continuation-in-part of Ser. No. 531,129 filed Sept. 2, 1983, now abandoned.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
2434625 |
Ruskin |
Jan 1948 |
|
3787585 |
Ueno et al. |
Jan 1974 |
|
Foreign Referenced Citations (2)
Number |
Date |
Country |
118499 |
Sep 1980 |
JPX |
486055 |
May 1938 |
GBX |
Non-Patent Literature Citations (2)
Entry |
Tetsuo Hamaoto et al, Jour. of Antibiotics, vol. 36 (1983), pp. 639-645, 646-650. |
John M. Venditti, Pharmacological Basis of Cancer Themotherapy, Publ. by The Williams & Wilkins Company (1975), pp. 245-270. |
Continuations (1)
|
Number |
Date |
Country |
Parent |
641984 |
Aug 1984 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
531129 |
Sep 1983 |
|